Gottheimer Urges Gilead to Expand Access to Investigational COVID-19 Treatment for Patients with Severe Symptoms

Doctors in North Jersey continue vying for access to COVID-19 treatment for patients fighting for their lives — like Bergenfield 34-year-old father of two, Michael Goldsmith

f t # e
GLEN ROCK, NJ, March 28, 2020 | comments

On Saturday, March 28, 2020, U.S. Congressman Josh Gottheimer (NJ-5) released the following statement:

“Gilead Sciences is continuing to deny access of its investigational COVID-19 drug remdesivir to some patients suffering from extreme symptoms of the disease — including some patients in North Jersey, like 34-year-old Bergenfield resident and father of two, Michael Goldsmith, who is currently suffering from extreme COVID-19 complications and fighting for his life.

I continue to be a strong supporter of the life sciences and pharmaceutical work that takes place in my District in North Jersey and all around the country. Now is the time for companies to expand their efforts and strengthen their commitment to effectively treating more patients, helping develop the cures we need, and provide access to those who need it most. Lives throughout New Jersey and across America are depending on it.”


f t # e